Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults

Journal of Virology

Volumn 76, Issue 21, 2002, Pages 11104-11112

  Barbour, Jason D ^a   Wrin, Terri ^a   Grant, Robert M ^a   Martin, Jeffrey N ^a   Segal, Mark R ^a   Petropoulos, Christos J ^a   Deeks, Steven G ^a  

^a Building 80 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CROSS RESISTANCE; DRUG SENSITIVITY; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; PHENOTYPE; PRIORITY JOURNAL; TREATMENT FAILURE; VIREMIA; VIRUS MUTATION; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS RESISTANCE;

ADULT; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; EVOLUTION; GENOTYPE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LONGITUDINAL STUDIES; PHENOTYPE; TIME FACTORS; TREATMENT FAILURE; VIRUS REPLICATION;

EID: 0036838224     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.76.21.11104-11112.2002     Document Type: Article

References (40)

1. Back, N. K., M. Nijhuis, W. Keulen, C. A. Boucher, B. O. Oude Essink, A. B. van Kuilenburg, A. H. van Gennip, and B. Berkhout. 1996. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J. 15:4040-4049.
2. + T cell counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J. Infect. Dis. 181:1808-1812.
3. Berkhout, B. 1999. HIV-1 evolution under pressure of protease inhibitors: climbing the stairs of viral fitness. J. Biomed. Sci. 6:298-305.
4. Bleiber, G., M. Munoz, A. Ciuffi, P. Meylan, and A. Telenti. 2001. Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J. Virol. 75:3291-3300.
5. Borman, A. M., S. Paulous, and F. Clavel. 1996. Resistance of human immunodeficiency virus type 1 to protease inhibitors: selection of resistance mutations in the presence and absence of the drug. J. Gen. Virol. 77:419-426.
6. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
7. Croteau, G., L. Doyon, D. Thibeault, G. McKercher, L. Pilote, and D. Lamarre. 1997. Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors J. Virol. 71:1089-1096.
8. Deeks, S. G., J. D. Barbour, R. M. Grant, and J. N. Martin. 2002. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 16:201-207.
9. Deeks, S. G., R. M. Grant, G. W. Beatty, C. Horton, J. Detmer, and S. Eastman. 1998. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS 12: F97-F102.
10. Deeks, S. G., N. S. Hellmann, R. M. Grant, N. T. Parkin, C. J. Petropoulos, M. Becker, W. Symonds, M. Chesney, and P. A. Volberding. 1999. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J. Infect. Dis. 179:1375-1381.
11. + T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J. Infect. Dis. 185:315-323.
12. Deeks, S. G., T. Wrin, T. Liegler, R. Huh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. MeCune, M. K. Hellerstein, and R. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
13. Diggle, P. J., K. Y. Liang, and S. L. Zeger. 1994. Analysis of longitudinal data. Oxford University Press, Oxford, United Kingdom.
14. Eastman, P. S., J. Mittler, R. Kelso, C. Gee, E. Buyer, J. Kolberg, M. Urdea, J. M. Leonard, D. W. Norbeck, H. Mo, and M. Markowitz. 1998. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy. J. Virol. 72:5154-5164.
15. Erickson, J. W., S. V. Gulnik, and M. Markowitz. 1999. Protease inhibitors: resistance, cross-resistance, fitness and the choice of initial and salvage therapies. AIDS 13:S189-S204.
16. - cells per cubic millimeter. N. Engl. J. Med. 333:1662-1669.
17. Frenkel, L. M., and J. I. Mullins. 2001. Should patients with drug-resistant HIV-1 continue to receive antiretroviral therapy? N. Engl. J. Med. 344:520-522.
18. Frost, S. D., M. Nijhuis, R. Schuurman, C. A. Boucher, and A. J. Brown. 2000. Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection. J. Virol. 74:6262-6268.
19. Goudsmit, J., A. de Ronde, E. de Rooij, and R. de Boer. 1997. Broad spectrum of in vivo fitness of human immunodeficiency virus type I subpopulations differing at reverse transcriptase codons 41 and 215. J. Virol. 71:4479-4484.
20. Grabar, S., V. Le Moing, C. Goujard, C. Leport, M. D. Kazatchkine, D. Costagliola, and L. Weiss. 2000. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann. Intern. Med. 133:401-410.
21. Groenink, M., R. A. Fouchier, S. Broersen, C. H. Baker, M. Koot, A. B. van't Wout, H. G. Huisman, F. Miedema, M. Tersmette, and H. Schuitemaker. 1993. Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science 260:1513-1516.
22. Hance, A. J., V. Lemiale, J. Izopet, D. Lecossier, V. Joly, P. Massip, F. Mammano, D. Descamps, F. Brun-Vezinet, and F. Clavel. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J. Virol. 75:6410-6417.
23. Hatano, H., S. Vogel, C. Yoder, J. A. Metcalf, R. Dewar, R. T. Davey, Jr., and M. A. Polis. 2000. Pre-HAART HIV burden approximates post-HAART viral levels following interruption of therapy in patients with sustained viral suppression. AIDS 14:1357-1363.
24. Hirsch, M. S., F. Brun-Vezinet, R. T. D'Aquila, S. M. Hammer, V. A. Johnson, D. R. Kuritzkes, C. Loveday, J. W. Mellors, B. Clotet, B. Conway, L. M. Demeter, S. Vella, D. M. Jacobsen, and D. D. Richman. 2000. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International. AIDS Society-USA panel. JAMA 283:2417-2426.
25. Huang, W., V. De Gruttola, M. Fischl, S. Hammer, D. Richman, D. Havlir, R. Gulick, K. Squires, and J. Mellors. 2001. Patterns of plasma human immunodeficiency virus type 1 RNA response to antiretroviral therapy. J. Infect. Dis. 183:1455-1465.
26. Kaufmann, D., G. Pantaleo, P. Sudre, and A. Telenti. 1998. CD4-cell count in HIV-1-infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Swiss HIV Cohort study. Lancet 351:723-724.
27. Larder, B. A., S. D. Kemp, and P. R. Harrigan. 1995. Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science 269:696-699.
28. Learmont, J. C., A. F. Geczy, J. Mills, L. J. Ashton, C. H. Raynes-Greenow, R. J. Garsia, W. B. Dyer, L. McIntyre, R. B. Oelrichs, D. 1. Rhodes, N. J. Deacon, and J. S. Sullivan. 1999. Immunologic and virologic status after 14 to 18 years of infection with an attenuated strain of HIV-1. A report from the Sydney Blood Bank Cohort. N. Engl. J. Med. 340:1715-1722.
29. Maeda, Y., D. J. Venzon, and H. Mitsuya. 1998. Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance. J. Infect. Dis. 177:1207-1213.
30. Marschner, I. C., A. C. Collier, R. W. Coombs, R. T. D'Aquila, V. DeGruttola, M. A. Fischl, S. M. Hammer, M. D. Hughes, V. A. Johnson, D. A. Katzenstein, D. D. Richman, L. M. Smeaton, S. A. Spector, and M. S. Saag. 1998. Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J. Infect. Dis. 177:40-47.
31. Martinez-Picado, J., K. Morales-Lopetegi, T. Wrin, J. G. Prado, S. D. Frost, C. J. Petropoulos, B. Clotet, and L. Ruiz. 2002. Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions AIDS 16:895-899.
32. Martinez-Picado, J., A. V. Savara, L. Sutton, and R. T. D'Aquila. 1999. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. J. Virol. 73:3744-3752.
33. Nijhuis, M., R. Schuurman, D. de Jong, J. Erickson, E. Gustchina, J. Albert, P. Schipper, S. Gulnik, and C. A. Boucher. 1999. Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS 13:2349-2359.
34. Petropoulos, C. J., N. T. Parkin, K. L. Limoli, Y. S. Lie, T. Wrin, W. Huang, H. Tian, D. Smith, G. A. Winslow, D. J. Capon, and J. M. Whitcomb. 2000. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob. Agents Chemother. 44:920-928.
35. Piketty, C., P. Castiel, L. Belec, D. Batisse, A. Si Mohamed, J. Gilquin, G. Gonzalez-Canali, D. Jayle, M. Karmochkine, L. Weiss, J. P. Aboulker, and M. D. Kazatchkine. 1998. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS 12:745-750.
36. Quinones-Mateu, M. E., S. C. Ball, A. J. Marozsan, V. S. Torre, J. L. Albright, G. Vanham, G. van Der Groen, R. L. Colebunders, and E. J. Arts. 2000. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J. Virol. 74:9222-9233.
37. Robinson, L. H., R. E. Myers, B. W. Snowden, M. Tisdale, and E. D. Blair. 2000. HIV type 1 protease cleavage site mutations and viral fitness: implications for drug susceptibility phenotyping assays. AIDS Res. Hum. Retroviruses 16:1149-1156.
38. Staszewski, S., V. Miller, C. Sabin, C. Schlecht, P. Gute, S. Stamm, T. Leder, A. Berger, E. Weidemann, A. Hill, and A. Phillips. 1999. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 13:951-956.
39. Zennou, V., F. Mammano, S. Paulous, D. Mathez, and F. Clavel. 1998. Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J. Virol. 72:3300-3306.
40. Zhang, Y. M., H, lmamichi, T. Imamichi, H. C. Lane, J, Falloon, M. B. Vasudevachari, and N. P, Salzman. 1997. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J. Virol. 71:6662-6670.